Clinical Trial Detail

NCT ID NCT02254772
Title TLR9 Agonist SD-101, Ipilimumab, and Radiation Therapy in Treating Patients With Low-Grade Recurrent B-cell Lymphoma
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Ronald Levy
Indications

marginal zone B-cell lymphoma

follicular lymphoma

B-cell lymphoma

CLL/SLL

Therapies

Ipilimumab + SD-101

Age Groups: adult

No variant requirements are available.